Month: December 2025

health news

1933 Industries Issues Reminder to Debenture Holders Ahead of December 22 Conversion Deadline and Highlights Positive Industry Developments

Staff December 19, 2025

VANCOUVER, BC / ACCESS Newswire / December 19, 2025 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCID:TGIFF) is...

Read MoreRead more about 1933 Industries Issues Reminder to Debenture Holders Ahead of December 22 Conversion Deadline and Highlights Positive Industry Developments
health news

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company’s Suite of Licenses and Proven U.S. Clinical Trial Supply Experience

Staff December 19, 2025

TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or...

Read MoreRead more about Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company’s Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
health news

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

Staff December 19, 2025

Financing included participation by healthcare-dedicated investors alongside existing shareholdersTORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN)...

Read MoreRead more about Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
health news

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

Staff December 19, 2025

HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extendedThe collaboration explores the effect...

Read MoreRead more about Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
health news

NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary, Good Salt Life, Inc., Launches Brands PurrGuard® and Dog Gone Odor®, EPA-registered Odor-killing Bacteria Chemistry for Companion Animals

Staff December 19, 2025

ATHENS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NDT Pharmaceuticals, Inc.’s (OTC: NDTP) wholly-owned subsidiary Good Salt Life, Inc., a pioneer...

Read MoreRead more about NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary, Good Salt Life, Inc., Launches Brands PurrGuard® and Dog Gone Odor®, EPA-registered Odor-killing Bacteria Chemistry for Companion Animals
health news

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Staff December 19, 2025

The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025...

Read MoreRead more about Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
health news

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

Staff December 19, 2025

CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and...

Read MoreRead more about Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
health news

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

Staff December 19, 2025

NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with...

Read MoreRead more about Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
health news

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

Staff December 19, 2025

MULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:...

Read MoreRead more about Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

You may have missed

health news

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Staff January 11, 2026
health news

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Staff January 11, 2026
health news

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

Staff January 11, 2026
health news

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Staff January 11, 2026
health news

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Staff January 11, 2026
error: Content is protected !!